65,437 trials
Arthritis, Rheumatoid
Primary: Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12…
Smoking · Smoking Cessation · Nicotine Dependence
Primary: Abstinence From Smoking — 131; 205 Participants — p=<.0001
Respiratory Infection
Primary: Number of Acute Respiratory Infections (ARIs) — 32; 48 events
Athletic Injuries · Sprains and Strains · Wounds and Injuries
Primary: Knee Flexion Angle and Trunk Flexion Angle After Activity Training With Feedback — 105.0; 41.0 degrees — p=<0.01
Graft vs Host Disease
Primary: Clinical Activity — 4; 4 participants
Major Depressive Disorder · Post-Traumatic Stress Disorder (PTSD)
Primary: Change in Glutamate Levels at Baseline and After Ketamine Administration as Confirmed by Positron Emission Tomography (PET) Imaging — 19; 14; 31; 14 percentage reduction
Bladder Cancer
Primary: Percentage of Participants With a Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed by the Independent Review Facility (IRF)…
Presbyopia
Primary: Ocular Comfort Assessment Following Instillation at Baseline and the Day Prior to Each Study Visit — 3.2; 3.3; 2.4; 2.2 units on a scale
Crohn Disease · Rectal Fistula
Primary: Number of Participants With Durable Fistula Healing — 7; 8 participants
Chronic Inflammatory Disorder · Arthritis, Rheumatoid
Primary: Pharmacokinetics: Plasma Concentration-Time Curve (AUC) — 1670; 1710; 1510; 1700 nanomoles*hours per liter (nmol*h/L)
Alcoholism · Alcohol Dependence · Post-Traumatic Stress Disorder
Primary: Posttraumatic Stress Disorder (PTSD) Symptom Scale - Interview (PSS-I-IV) — 27.1; 30.3; 27.7; 27.5 units on a scale
Chronic Obstructive Pulmonary Disease
Primary: Percentage of Patients to Experience Any Treatment-emergent Adverse Event — 56.8; 65.9; 61.3; 67.5 Percentage of participants
Heart Failure
Primary: Distribution of "Improved", "Unchanged" and "Worsened" Patients as Defined Per M. Packer's Clinical Composite Score — 11; 7; 10; 16 participants
Influenza
Primary: Number of Subjects Reporting Solicited Adverse Events (AEs) Following Vaccination With Either TIVc or TIV by Overall Age Group — 149; 41; 89; 18 Subjects
Chronic Kidney Disease · Cardiovascular Disease
Primary: In Vitro Lipoprotein Functions — 20.8; 26.5 Percentage of cholesterol content